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Abstract
Background: The performance of the tetracycline controlled transcriptional activation system (Tet system) depends
critically on the choice of minimal promoters. They are indispensable to warrant low expression levels with the
system turned “off”. On the other hand, they must support high level of gene expression in the “on"-state.
Results: In this study, we systematically modified the widely used Cytomegalovirus (CMV) minimal promoter to
further minimize background expression, resulting in an improved dynamic expression range. Using both plasmid-
based and retroviral gene delivery, our analysis revealed that especially background expression levels could be
significantly reduced when compared to previously established “standard” promoter designs. Our results also
demonstrate the possibility to fine-tune expression levels in non-clonal cell populations. They also imply differences
regarding the requirements for tight regulation and high level induction between transient and stable gene
transfer systems.
Conclusions: Until now, our understanding of mammalian transcriptional regulation including promoter
architecture is limited. Nevertheless, the partly empirical modification of cis-elements as shown in this study can
lead to the specific improvement of the performance of minimal promoters. The novel composite Ptet promoters
introduced here will further expand the utility of the Tet system.
Background
The Tet system is the most widely used inducible gene
expression technology in eukaryotes, for both, in vivo
and in vitro applications. Based on its original design
[1], now frequently referred to as „Tet-Off” system, it
experienced its first major modification by the introduc-
tion of the „Tet-On” system [2]. Both systems respond
in opposite ways to the presence of tetracyclines (e.g.
doxycycline, Dox), by either inactivating (Tet-Off) or
activating gene expression (Tet-On). The difference is
based on amino acid exchanges in the synthetic tran-
scription factors employed, tTA and rtTA respectively,
reversing the response of the DNA binding domain to
the presence of the allosteric effector Dox. Initially both
systems relied on the same composite tet-responsive
promoter, Ptet-1 [1]. Subsequent attempts to broaden
the utility and performance of the Tet system focused
on transactivator manipulation: nuclear localization
sequences were introduced [3,4], codon usage was
optimized [5-7], potential splice sites were removed [6]
and activation domains have been exchanged [8,9]. The
most significant advances, however, came from genetic
approaches to identify improved versions of Tet-On
type transactivators. These experiments aimed to
i m p r o v et h ed y n a m i cr a n g e ,b ye i t h e rar e d u c t i o no f
residual DNA binding (and thus transcriptional activa-
tion) in the non-induced state or enhancement of acti-
vation in the induced state. In this context, the most
notable transactivator alleles were identified in yeast [6]
and, through enforced retroviral evolution, in human
cells [10,11].
While these approaches focused on improving the
dynamic range of the Tet system via modified transacti-
vators, it appeared interesting to explore, whether the
Tet system could also be improved by manipulation of
the cis-acting tet-responsive promoters. The initially
introduced Ptet-1 [1] is based on a minimal promoter
fragment derived from the CMV immediate early pro-
moter. Various alternatives were introduced over the
years, like those further truncating the CMV minimal
promoter of Ptet-1 [12-15], constructs based on the
* Correspondence: rainer.loew@eufets.com
1EUFETS GmbH, 55743 Idar-Oberstein, Germany
Full list of author information is available at the end of the article
Loew et al. BMC Biotechnology 2010, 10:81
http://www.biomedcentral.com/1472-6750/10/81
© 2010 Loew et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.HSV Tk promoter [1], the MMTV long-terminal repeat
promoter [16,17] and the HIV-1 long-terminal repeat
promoter [17]. Several of these Ptet variants had their
advantages under the specific conditions tested, with e.g.
a “second-generation tetracycline regulatable promoter”
[13] showing up to 5 orders of magnitude in inducible
gene regulation experiments using the Tet-off regulation
principle. However, with the exception of Ptet-14 (com-
monly known as Ptight [18]), which was derived from
Ptet-1 by empirical modifications and displayed a sub-
stantially reduced background expression, none of these
promoter constructs is widely used.
Here we present our results with a series of novel Ptet
variants. Systematically introduced alterations were gen-
erated to minimize background expression while main-
taining high levels of induced expression. To place these
experiments in a proper context, it is worthwhile to
initially distinguish between the different sources of
such background expression. Especially in a comparative
analysis of transient transfection and stable transduction
experiments as presented here, their individual contribu-
tion can be readily addressed. Considering the various
sources of background expression is an essential
requirement when expression systems based on the
transactivation paradigm are engineered and is not
restricted to the Tet system.
In principle, background expression can be triggered
by residual binding of transactivators to their cognate
binding sites. This would be the case when expression,
driven by a Ptet promoter, is higher in a tet transactiva-
tor-positive cell line in the off-state as compared to an
otherwise isogenic tet transactivator-negative cell line.
Secondly, background expression due to e.g. enhancers
or other sequence elements able to act at long-range on
Ptet is to be expected and has indeed been frequently
observed. Such effects can be avoided by targeted inser-
tion of the Ptet driven transcription unit into an appro-
priate genomic locus [19] or suppressed by the use of
insulator elements [20].
Thirdly, background expression is also influenced by
the accessibility of the Ptet, which is determined by epi-
genetic parameters such as DNA methylation and inte-
gration into chromatin structures.
Lastly, background expression might be intrinsic for a
given Ptet due to hidden binding sites for transcription
factor. Reduction of this intrinsic background was the
goal of the current study. For this purpose, we designed
novel Ptet promoter variants with low background activ-
ities and highly induced expression levels by stepwise
modification of Ptet-1. Already known functional cis ele-
ments of the promoter where exchanged, others expected
to optimize its performance were introduced and those
suspected to impede performance where deleted. This
strategy proved successful when the new Ptet promoter
variants where quantitatively characterized in a plasmid
vs. retrovirus backbone and examined in different cell
lines. Our results revealed that several novel Ptet promo-
ters, and in particular, Ptet-T6, are superior to Ptet-1 and
Ptet-14 with regard to low background levels in the off-
state, while retaining a high activation potential.
Results
Experimental strategy
The Tet system with its key elements Ptet and the tetra-
cycline controlled transcriptional activators (tTA and
rtTA) is outlined in Figure 1A. Ptet-1 is composed of a
CMV derived minimal promoter linked downstream to
an array of seven tet operators. The focus of this work
was the further optimization of Ptet-1 via reduction of
background expression while maintaining or even
improving the levels of induced expression. Such com-
bined effects would result in an improved range of tran-
scription control.
For comparison Ptet-1 and Ptet-14 were included in
the study. As outlined in Figure 1B, these two promoters
differ in the spacing between tet operators. The center-
to-center distance of neighboring operators is 42 nt for
Ptet-1 versus 36 nt for Ptet-14. Moreover, their respec-
tive CMV minimal promoter moieties differ in length.
The T-series of Ptet promoters introduced here
all contain a tet operator heptamer with 36 nt spacing
(Figure 1C). In contrast to Ptet-14 where the spacer
sequences between the operators are identical we used
randomized spacer sequences (additional file 1), thus
minimizing the symmetry within the operator region.
This accounts for the sensitivity of viral vectors to palin-
dromic sequences due to the strand displacement
mechanism [21,22], which may lead to gradual loss of
operators during reverse transcription [17,23]. Replacing
the operator heptamer of Ptet-1 with this newly
designed operator array resulted in Ptet-T1.
Subsequent modifications of the minimal promoter
moiety of the Ptet promoters followed a rational design
strategy, stepwise altering known functional sequence
elements within the CMV minimal promoter as used in
Ptet-T1. Introducing point mutations to Ptet-T1 led to
consensus sequences of the TATA-box and the TFIIB
binding site (BRE [24,25]) in Ptet-T2. The BRE
upstream the TATA-box could possibly enhance tran-
scriptional initiation upon induction with acidic
domain-type transactivator VP16 [26-29], while reducing
background transcription of promoters in the non-
induced state [26,30]. Deletion of the CMV 5’-UTR led
initially to Ptet-T3 with truncated downstream promoter
element (DPE, [31]). Ptet-T4, exhibiting a rudimentary
5’-UTR, contained only the CMV-initiator element (Inr,
[32]) directly followed by the start codon. In order to
restore an average length 5’-UTR, we decided to
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RNA virus (turnip yellow mosaic virus, TYMV) fused 3’
to the Inr sequence of Ptet-T4. This sequence contains
only few cis elements known to be important for pro-
moter regulation in the animal kingdom (Transfac data-
base; http://www.gene-regulation.com/pub/databases.
html). The transcription factor binding sites found, for
RFX-1 and AP-4, were eliminated by point mutations,
resulting in Ptet-T5. Further modifications of the
TYMV 5’-UTR led to Ptet-T6 and Ptet-T7. As discussed
in more detail below, these constructs are devoid of
potential splice signals (5’-AGGT-3’ to 5’-AGCT-3’;s e e
additional file 2) and hairpin structures [33,34] that
could confer cap-independent translation initiation.
We were primarily interested in functional properties of
the newly designed Ptet promoters in heterogeneous, non-
clonal cell populations. We therefore evaluated these pro-
moters by transient transfection of plasmid DNA, as well
as g-retroviral transduction resulting in stable cell pools.
Initial characterization of the new promoters in
a plasmid backbone
The new Ptet promoters as well as the control con-
structs (full length CMVie promoter (-673/+75), Ptet-1
and Ptet-14) were all integrated in an identical manner
into the plasmid pUHC-131-1 [35] containing firefly
luciferase as the reporter gene. Transfection into tet
transactivator-positive HeLa-EM2 cells [19] was per-
formed in the presence and absence of Dox. The results
as shown in Figure 2 demonstrate that all the new Ptet
promoters were highly inducible. Ptet-T1 displayed a
5-fold higher induced expression level than Ptet-1,
although both contain the identical CMV minimal pro-
moter. Ptet-T1 also displayed a 6-fold reduction of non-
induced background expression resulting in a regulation
factor of at least 13000-fold vs. 400-fold for the original
Ptet-1. This improvement is solely based on the new
operator heptamer introduced into otherwise identical
constructs. The expression characteristics of Ptet-T2
were similar to that of Ptet-T1, differing only by the
introduction of a consensus BRE in the T2 construct.
Modifications of the 5’-UTR (constructs Ptet-T3 to-
T7) led to slightly reduced expression in the induced
state when compared to Ptet-T2. Still, even the weakest
of these Ptet promoters, Ptet-T6, displayed a slightly
higher induced expression level than the original Ptet-1.
In line with our experimental objective, the more
interesting outcome of the stepwise alteration of the
Figure 1 Outline of the Tet System and the Ptet promoters. (A) The tet-responsive transactivator (here tTA, i.e. Tet-Off system) is
constitutively expressed in the cell. tTA homodimers bind to the heptameric tet operator sequence (tetO7) in the absence of Dox (a tetracycline
derivative). They dissociate from their recognition sites after Dox addition. The Dox response would be reversed for “Tet-On” type transactivator
lines also used in this study (C = CMV minimal promoter). (B) Comparison of Ptet-1, the originally described Ptet promoter and the commercially
available Ptet-14 ("Ptight”). Both consist of tet operator heptamers created by monomer ligation via compatible restriction sites (Xho/Sal), but
with differently spaced operator centers. The CMV-minimal promoters differ in size, but both contain the authentic TATA-box and initiator
sequence (Inr). (C) The newly designed Ptet promoters are shown, consisting of a tet operator heptamer with 36nt spacing, and randomized
fusion points between all the operators. The CMV derived minimal promoters of the T2-T7 Ptet promoters all have a consensus ("c”) TATA-box
and TFIIB binding site but differ in the composition of the 5’ UTR as outlined in the text. Point mutations are indicated by (*), deletions by
dashed lines. Nucleotide positions are given relative to the transcriptional start site (+1). The initiator (Inr) and downstream promoter element
(DPE) is indicated.
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further reduction of background expression in the off-
state, already obvious from shortening the CMV leader
sequence in Ptet-T3 and Ptet-T4 (> 30-fold reduction
when compared to Ptet-1). Introduction of the TYMV
5’-UTR and its variants (Ptet-T5, -T6 and -T7) reduced
background expression even further. Especially Ptet-T6
displayed significantly lower background activity, more
than 100-fold reduced compared to Ptet-1 and about
10-fold compared to Ptet-14. This resulted in regulation
factors of about 50000-fold in these transient transfec-
tion assays (Ptet-1 = 400-fold; Ptet-14 = 6200-fold).
It should be noted here that for several of the Ptet
promoters the luciferase values measured by us were
very close to instrument background. Compared to our
established protocols we increased the amount of trans-
fected plasmid DNA in order to obtain readings that
could be reliably quantified (see Methods and legend of
figure 2).
Performance of the new regulatory units after
retroviral transduction
The newly designed Ptet promoters were integrated into
the ES.1 g-retroviral vector (Figure 3A) containing lmg*
as the reporter gene (Figure 3B). Lmg* is a dual reporter
gene providing GFP as well as luciferase activity (see
Methods). This allowed us to determine differences in
unregulated background expression with exceptional
sensitivity in luciferase assays without sacrificing the
option of single cell resolution via GFP measurements.
Infections of HtTA-1 cells (expressing the tet-off type
transactivator tTA; [1]) were performed at low MOI
(0.06-0.12) under induced conditions (to allow cell
enrichment of all GFP positive transductants). This
ensured that the majority of the transduced cells contained
as i n g l ei n t e g r a t e dc o p yo ft h er e s p o n s eu n i t [ 3 6 ] .T h e
results shown in Figure 3C were similar but not identical
to those of the transfection experiments (Figure 2). All
new Ptet promoters displayed high expression levels in the
induced state, slightly higher than Ptet-1.
A direct comparison of reporter activities in absolute
terms is not possible between the different experiments,
as we had to switch from luciferase activity normalized
to a second co-transfected reporter (transient transfec-
tions; Figure 2) to luciferase activity normalized to the
protein content of cellular extracts (stable transductions;
Figure 3). However, the pattern of background expres-
sion levels in the off-state of the system were similar
between the different Ptet promoters when comparing
the results shown in Figure 2 with those of Figure 3. As
in case of the plasmid transfections the Ptet-T6 trans-
duced cell populations displayed the lowest background
Figure 2 Transient transfection analysis of the new Ptet promoters in HeLa-EM2 cells. Left panel: Firefly luciferase activities after
transfection of HeLa-EM2 cells with the new Ptet promoter driven reporter constructs were determined in the on-(+Dox) and off-state (-Dox) of
the system. Values were normalized to the activity of a cotransfected internal standard (beta-galactosidase reporter). Statistical comparison of
Ptet-1 and Ptet-14 with Ptet-T6 via students t-test was performed with Graph Pad Prism version 5.03 software (** = p-value < 0,01, *** = p-value
< 0.001, n.s. = not significant). High amounts of luciferase reporter plasmids were transfected to achieve relative light unit readings above
instrument background that could be reliably quantified. For example, in this experiment the instrument background (identical to mock
transfected cells) was 1,5 × 10
2 rlu while that of extracts from Ptet-T6 transfected cells (-Dox) was 3,5 × 10
2 rlu. Right panel: Regulation factors for
the individual Ptet promoters from the analysis shown left. The results shown are the mean of three independent transfection experiments, the
error bars represent the SEM.
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notable difference resulted from the introduction of the
BRE (transition from Ptet-T1 to -T2), which had a
much more pronounced effect on background expres-
sion upon chromosomal integration.
Comparison of the doxycycline dose response of Ptet-1
and Ptet-T6
Next, we asked whether the altered Ptet promoter archi-
tecture would result in dose response changes of the
regulatory system towards Dox. These parameters were
previously established for Ptet-1 in HeLa cells. HeLa-
EM2 cells were transduced by ES.1-Ptet-1(lmg*)p or
ES.1-Ptet-T6(lmg*)p retroviral SIN-vectors. Purified
populations were incubated in the presence of the indi-
cated Dox concentration for 96 hours, harvested and
analyzed for eGFP fluorescence and luciferase actvity
(Figure 4A and 4B). The GFP data confirm that Ptet-T6
can reach a slightly improved expression level when
compared to Ptet-1. Since in the non-induced state, the
mean fluorescence of both cell populations is too close
to the background level of HeLa-EM2 cells no meaning-
ful conclusion (Figure 4A) can be drawn.
Taking advantage of the luciferase activity of the
lmg* reporter, simultaneous luciferase measurements
revealed that background expression in the off-state of
Ptet-T6 is 15-fold below that of Ptet-1, in line with the
previous analysis (Figure 4B). The combination of
reduced background and slightly enhanced induced
expression level resulted in an about 30-fold increased
regulation range. The maximum induction for both
promoters had been reached at 300 ng Dox/ml; further
increase of the effector concentration was without
effect.
Figure 3 Retroviral transfer of the new Ptet promoters. (A) The different regulatory units were inserted into the g-retroviral self-inactivating
(SIN) vector „ES.1”. The U3-enhancer elements (ΔU3) were deleted from the provirus, while the enlarged packaging region (ψ,ψ+) as well as the
native splice acceptor (SA) located in the pol/env region of the virus were retained. In order to enhance viral titers and translational efficiency, a
woodchuck posttranscriptional regulatory element (WPRE) was integrated 3’-to the reporter gene. (B) The lmg* dual reporter was used
throughout all experiments with the viral vectors. The corresponding gene consists of the firefly luciferase open reading frame (orf), with deleted
stop codon, the 3’-half of the troponin C a-helix5 and the eGFP orf with the deleted start codon. (C) Left panel: Determination of specific
luciferase activity (relative light units, rlu) that were obtained from transduced, FACS enriched HtTA-1 cell populations. Statistical comparison was
done as described in figure 2. Right panel: Regulation factors for the individual Ptet promoters from the analysis shown left. The results shown
are derived from at least two cell populations generated independently. Each population was analyzed two to three times; the error bars
represent the SEM.
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between 10 and 100 ng Dox/ml is similar for both Ptet
promoters, indicating an identical synergistic response
of both promoters to increased occupancy of the opera-
tors by tet-transactivators.
The FACS analysis at single cell resolution (Figure 4C)
indicates that all cells responded to induction, but not
homogenously. Upon partial induction (30 ng Dox/ml)
the expression level of the individual cells differed
widely. It has to be emphasized that the cell population
analysis was genetically heterogeneous with respect to
insertion of the reporter unit. Again, the overall charac-
terization of the two Ptet promoters analyzed revealed
no major differences in the dose response parameters.
Fine-tuning of transgene expression
The results obtained with the new Ptet promoters, espe-
cially Ptet-T6, led us to routinely employ these promoters
in ongoing research projects in our laboratories. The fol-
lowing results were derived from a project aiming at the
conditional expression of erbB2 in breast cancer cell lines.
A tet transactivator-positive MDA-MB231.ro cell line
Figure 4 Dose response analyses of Ptet-1 and Ptet-T6 in transduced HeLa-EM2 cell populations. (A) Determination of dose response via
eGFP function of lmg*. Mean fluorescence units (mfu) are given for the complete populations (≥ 95% purity). For value ranges see insets in “C”.
(B) The simultaneous analysis of identical populations for specific luciferase activity of lmg*. The rlu values ranged from about 4.5 × 10
4 (± 2.8 ×
10
3) to 1.6 × 10
7 (± 4.7 × 10
5) rlu/μg for Ptet-1 and 2.9 × 10
3 (± 1.1 × 10
2) to 2.3 × 10
7 (± 3.9 × 10
5) rlu/μg for Ptet-T6 in the off-and on-state of
the system. (C) FACS-analysis of a representative cell population for Ptet-1 and Ptet-T6 promoters transferred by the viral vectors. Mfu values of
the whole population were given as inset. The cellular background of the GFP-negative Hela-EM2 parental cell line was 1.83. The Dox
concentrations used are indicated. Induction was for 96 hours. Results shown in figs. A and B were obtained from two independently generated
populations for each vector.
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Page 6 of 13expressing rtTA-S2 [6] has been previously established (R.
L., unpublished results). Transduction of this clone was
performed with a retroviral SIN-vector, ES.1-T6(erbB2)p
(Figure 5A), in which the erbB2 (or Her2/neu, [37,38])
open reading frame was under control of Ptet-T6. As the
ErbB2 protein is located on the cell surface, it is well sui-
ted for detection and selection of the transduced popula-
tion by FACS.
The results of the cell-based analysis (Figure 5B, triple
panel) of the purified population showed, that (i) erbB2
expression was tightly regulated in these experiments
with no recognizable background expression in the off-
state, (ii) despite looking at non-clonal pools expression
could be adjusted to intermediate levels by titrating
D o x ,a n d( i i i )c e l l sc o u l db em a i n t a i n e da tac h o s e n
expression level over a prolonged period of time. This
time course analysis was terminated on day 14. Interest-
ingly, prolonged full induction (1000 ng Dox/ml) led to
the disappearance of erbB2 cells, showing highest
expression levels, as can be seen from the asymmetric
steep drop of the right shoulder of the expression profile
peak. Thus, the expression level appears to reflect the
maximum long-term expression level of erbB2 tolerated
by those cells. The only other recognizable difference in
the expression profiles was a slight „compression”
of intermediate expression at 250 ng/ml Dox, as the
Figure 5 Transduction of a Ptet-T6 regulated erbB2 expression unit into MDA-MB231.Ro cells. (A) g-retroviral SIN-vector used to transfer
erbB2 into rtTA-S2-positive MDA-MB231.Ro target cells. (B) FACS-analysis of transduced cell populations induced for the indicated time and Dox
concentrations. The expression of the erbB2 transgene was detected by a monoclonal antibody (mAB ALX-804-573; Alexis) in combination with a
fluorescence labeled secondary antibody (donkey anti mouse IgG-FITC, affipure, Jackson Immuno Res.). Mean fluorescence units (mfu, blot inset)
are given for the complete population (≥ 92% purity). Clone #19 was derived from this population by limiting dilution.
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ently reduced after prolonged growth under these condi-
tions. Given the non-clonal origin of this cell
population, individual cells behaved remarkably similar.
Still, for certain applications, like analyzing pharmacolo-
gical responses to varying densities of cell surface recep-
tors, the homogeneity under intermediate expression
conditions may not be sufficient for reliable results.
Thus, we examined whether respective homogeneous
cell populations, derived from cell clones, would
improve the situation. The example shown in Figure 5B,
lower panel, demonstrates that this is indeed the case.
Further suppression of background expression could
already be observed in the vast majority of cells, but the
precision of partial induction was markedly improved by
clonal isolation of cells harboring Ptet-T6.
Discussion
Our goal was to improve the dynamic range of tetracy-
cline regulated transcription in such a way that tight,
virtually background-free non-induced expression can
routinely be obtained when working with non-clonal
cell populations. The Tet system in its current config-
uration has proven its capacity to achieve such back-
ground free expression, as widely documented in the
literature. However, most of these studies relied on clo-
nal analysis of transgenic cells, thereby eliminating cell
clones with less favorable properties, an often laborious
process which at times might even be impractical, for
example in the genetic engineering of primary cells. By
using previously established and well-characterized
transactivator-positive cell lines we restricted our efforts
solely to cis elements of tet-controlled transcription
units, the tet-responsive promoters. We investigated if
gene expression regulated by a rationally designed series
of new Ptet promoters would be superior over the
widely used original Ptet-1 promoter and its derivative
Ptet-14 (Ptight), particular by further reducing back-
ground expression of tet-regulated transcription units
while maintaining fully-induced expression levels. We
conclude that the reduction of the Ptet background
expression reported here is exclusively due to the low
intrinsic background of these new tet-responsive promo-
ters. Their side-by-side analysis (together with the pre-
viously characterized Ptet-1 and Ptet-14) in different
established tet transactivator-positive cell lines elimi-
nated the possibility that effects like transactivator abun-
dance or differences in tTA-vs. rtTA-mediated
transcription control would influence our conclusions.
Moreover, the tet operator sequences themselves are
identical in all new Ptet promoters used and any poten-
tial residual transactivator affinity to the operators
would not have any influence on the outcome of our
study. Lastly, we excluded a systematic distortion of our
results by the possible occurence of integration site-
specific or epigenetic effects through parallel analysis of
all Ptet promoters in transient transfection assays.
The initial transition from Ptet-1 to Ptet-T1 resulted
in a more than 5-fold lower background expression in
transient transfection assays. This effect was less pro-
nounced after viral transduction, possibly somewhat
overridden by the preference of g-retroviral vectors for
promoter-proximal integration [39] and the resulting
elevated background expression levels. In any case, the
improvements observed are solely due to the newly
designed tet operator heptamer with 36 nt spacing
between the centers, as the hCMV minimal promoter
(-53/+75) remained unaltered. So far, the relative contri-
bution of spacer length variations versus alterations of
nucleotide sequences separating them remains unclear.
Changes in the phasing of bound transactivators cannot
account for different background expression levels, only
for differences in activated expression. It is interesting
to note, that for the available 36 nt spaced operator con-
s t r u c t s([ 1 3 ] ;t h i ss t u d y )v a r ying induction levels were
obtained compared to a 42 nt operator spacing in the
context of otherwise identical promoters. In contrast to
our own results (Ptet-1 vs. Ptet-T1) showing an
increased inducible expression level with the 36 nt
spaced operators, the study of Agha-Mohammadi
showed a reduction in induced expression ( [13];
pCMV*-2 vs. p8tetO-36). So far we do not have an
explanation for these differences.
The first step towards improving the regulatory prop-
erties of the CMV minimal promoter was the introduc-
tion of a high affinity TFIIB binding site (BRE, [25])
upstream of a consensus TATA-box into Ptet-T1. This,
other than the changes in the operator heptamer, led to
a reduction of background activity most pronounced
a f t e rs t a b l ei n t e g r a t i o no ft h eP t e t - T 2b yar e t r o v i r a l
vector. These results are in line with published data that
implicate a negative effect on basal transcription levels
for such promoter modifications without affecting the
activated levels of transcription [26]. In addition, the
composition of minimal promoters with respect to cis
elements or the interaction of different acidic activation
domains with TFIIB may play a significant role in the
process of non-induced and induced transcription, and
might be modulated depending on the transacting fac-
tors available in a given cell type [30,40,41].
To further reduce the unregulated background expres-
sion we truncated the 5’-UTR of the CMV-minimal pro-
moter. Deletions of promoter elements within the
leader, e.g. the DPE, have been shown to improve the
signal to noise ratio of the minimal promoter [13,18].
Indeed, a direct comparison of Ptet-14, Ptet-T3 and
Ptet-T4 with Ptet-1 by transfection, revealed a strongly
reduced background expression in the off-state for these
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Thus, in the transient state the expected reduction of
background expression by the BRE became functional
only after removal of the DPE element [31]. A pro-
nounced reduction of baseline expression of Ptet-T3
and Ptet-T4 vs. Ptet-14 suggests that the suppressing
effect of TFIIB on background transcription was partly
masked by the DPE element. However, the effect of
deleting the DPE might not be directly related to the
function of the BRE.
In case of Ptet-T4 we relied on an unusually short
5’-UTR. Given the importance of untranslated leader
regions for the functionality of mRNAs and reconciling
their average length of around 200 nt [42] we tried to
increase their length without losing the gains in dynamic
range. In order to increase the size of the untranslated
leader, a 5’-UTR fragment of the Turnip Yellow Mosaic
virus (TYMV, [34]), was fused downstream to the resi-
dual CMV sequence of Ptet-T4. This leader was chosen
because we assumed that cis-elements of the plant king-
dom will not or only by chance be effective in the mam-
malian background. Indeed, the unregulated background
expression was further reduced by Ptet-T5. The elimina-
tion of two hairpins within the TYMV 5’-UTR fragment
[33] resulted in further reduction of background expres-
sion in the off-state of the Tet-system. This holds true
for both, the transient and the stable approach, since
Ptet-T6 displayed a 50000-fold up-regulation of gene
expression in the plasmid based system (Figure 2) and
about 10000-fold after its stable integration by a g-retro-
viral vector (Figure 3).
Among all the different promoter designs tested, Ptet-
T6 was consistently found to be the optimal Ptet promo-
ter. We are currently using this promoter routinely in
our laboratories when setting up tet-responsive stable
cell lines. Ptet-T6 promoter has been successfully tested
in stable cell lines as diverse as HEK293, primary human
fibroblasts and an avian cell line (MG, unpublished
results). Here we also showed that the Dox dose response
of this promoter was unaltered when compared to the
original Ptet-1, allowing an efficient, titratable expression
control even in transfected cell populations. In many
applications these improvements will allow tight control
over transgene expression while omitting the time con-
suming step of clonal isolation. However, our results for
the comparative analysis of pooled vs. clonal isolates of
erbB2 expressing cells indicated that, obviously, for the
precise adjustment of intermediate level expression the
pool strategy is not optimal. Indeed, pools showed rather
heterogeneous expression levels under these induction
conditions, most likely due to integration site effects with
individual loci following their inherent partial induction
schemes. This would be expected from differences in e.g.
chromatin packaging. Considering the different causes
responsible for background expression in the off-state,
s u c he f f e c t sh a v et ob ea d d r e s s e db ym e a n so t h e rt h a n
optimizing Ptet promoters for their lowest level of intrin-
sic background expression.
Conclusion
This study demonstrated the feasibility to further
improve tetracycline responsive promoters, especially for
reduction of background expression of the Tet regula-
tory system in the off-state. T oc o n f i r mt h a tt h en e w l y
created Ptet design is of general use, the promoters
were analyzed in two different assay systems, namely
following transient transfection or otherwise chromoso-
mal integration. Given our limited understanding of
many aspects of mammalian promoter architecture,
modifications of cis elements will always be partly
empirical. The results presented here nevertheless show,
that some of the promoter elements tested, display simi-
lar behavior whether analyzed in the context of Ptet
promoters or in their original promoter environment.
From our previous experien c ew ea r ec o n f i d e n tt h a t
these findings from different cell culture systems will
hold up in animal experiments, although this has yet to
be proven. Thus, we anticipate that these novel Ptet
promoters will contribute to further refining and enhan-
cing the Tet technology for in vivo and in vitro use.
Methods
Cell culture
293T cells (ATCC # CRL-11268) were cultured in Dul-
becco’s modified Eagles medium (DMEM, Invitrogen)
supplemented with 10% heat inactivated fetal calf serum
(FCS, PAA) at 37°C, 5% CO2. HtTA-1 [1] and HeLa-
EM2 cells [19] were cultured in Modified Eagles Med-
ium (MEM, Invitrogen) supplemented with 10% heat
inactivated FCS at 37°C, 5% CO2. The HtTA-1 cell line
expressed the originally described tet-responsive transac-
tivator tTA, active in the absence of Dox (Tet-Off),
while HeLa-EM2 cells express the codon optimized M2-
reverse transactivator [6] in the cellular background
which is fully active around 300 ng Dox/ml (Tet-On).
The MDA-MB231 cells, a human breast cancer cell
line (ATCC #HTB-26), modified to constitutively
express the S2-reverse transactivator, termed MDA-
MB231.Ro. rtTA-S2 is an alternative codon-optimized
reverse transactivator, that is fully active in the presence
of 1000 ng Dox/ml [6]. Cultivation is performed at 37°
Cw i t h o u tC O 2 in Leibovitz L-15 medium (Invitrogen,
#11415-049), supplemented with 10% FCS and 2 mM
L-glutamine.
Cultures were split at 70-80% confluence. Cells were
harvested after washing with PBS by incubating for 3-5
min with PBS/EDTA (0,8 mM), before being transferred
into fresh medium or being used for analysis.
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Transient production of viral vectors was carried out
essentially as described earlier [17]. Briefly, about 1.5 ×
10
6 293T cells were transferred to 60 mm dishes the day
before transfection. A total amount of 15 μg plasmid DNA
with 5 μg each of pHIT60 (gag/pol expression plasmid;
[43]), of pczVSV-G (VSV-G envelope expression plasmid;
[44]) and of the transfer vector was transfected via lipofec-
tion with the TransIt293 reagent (Mirus, CA) as recom-
mended by the supplier. 16-18 hours after transfection the
cells were incubated in medium supplemented with Na-
butyrate (5 mM) for 6-8 hours. The culture supernatant
was harvested 16-18 hours following medium exchange,
filtrated (0.45 μm) supplemented with polybrene (8 μg/ml,
SIGMA), aliquoted and stored at -80°C for later use.
All titrations were performed on HtTA-1 cells via
serial 2-fold dilution of supernatants (5-10-20-40-80-
160-fold) containing infectious particles (IP). Briefly, 2 ×
10
5 cells were transferred to a 6-well dish the day before
infection. 24 hours later, medium was replaced by 1 ml
fresh culture medium, premixed with vector containing
supernatant. About 16-20 hours later the incubation
medium was replaced by fresh medium and cells were
cultivated under induced conditions. FACS analysis was
performed about 96 hours post transduction. Vector
titers were determined according to the number of GFP
positive cells (4 × 10
5 cells × % GFP-pos/100), multi-
plied with the dilution factor as well as a correction fac-
tor 2 to account for cell division during infection. The
titers for all vectors described in this work were in the
range of 1-3 × 10
6 infectious particles (IP)/ml.
Establishing transduced cell populations
About 4 × 10
5 cells (HtTA-1, HeLa-EM2 or MDA-
MB231.Ro) were infected with serial dilutions of the
transiently produced vectors and induced for four to
five days with (1000 ng Dox/ml, HeLa-EM2, MDA-
MB231.Ro) or without Dox (HtTA-1). All GFP-positive
cells of appropriate infected cell populations (1-3% posi-
tive to ensure mostly single copy integrates) were used
for the enrichment by fluorescence activated cell sorting
(FACS). Pool sizes were adjusted to always exhibit >
10000 independent clones by multiple independent
infections. For each of the Ptet promoter driven reporter
constructs populations of ≥ 9 0 %p u r i t yw e r eu s e d
throughout the experiments.
Determination of luciferase activity
Transient transfection by lipofection and reporter assays
for Ptet promoter driven firefly luciferase and CMV pro-
moter driven beta-galactosidase (internal transfection
control) were performed as described [45]. For each
well of a 6-well plate 0.5 ug of luciferase reporter had to
be transfected to obtain reliable readings for non-
induced cultures. The luciferase activity of HeLa-EM2
and HtTA-1 cells was indistinguishable from the techni-
cal background in untransfected populations.
Purified transduced cell populations were cultivated in
the off-state for at least 10 days. This is necessary
because of the prolonged half life of luciferase in the
fusion protein lmg* and the high expression levels
reached in the induced state (see below). Induction
experiments were started by splitting about 1 × 10
5 off-
state cells into cell culture medium with (500-1000 ng/
ml) or without Dox. After 96 hours the cells were har-
vested with PBS/EDTA and used for analysis of fluores-
cence and luciferase activity in the on-and off-state. The
lyses of the cells and treatment of samples was essen-
tially as described [46]. Specific luciferase activity was
calculated after determining protein concentration of
the samples by the method of Bradford [47]. Treatment
of cells was similar for the dose response experiments,
except that here the medium was exchanged daily (sup-
plemented with the indicated Dox-concentrations) as a
precautionary measure to account for the possible
degradation of Dox at very low concentrations.
Synthesis of the dual reporter gene: lmg*
To facilitate the simultaneous determination of reporter
activity in cell populations as well as in individual cells
contained herein, we generated a fusion protein consist-
ing of firefly luciferase and eGFP.
T h er e p o r t e rg e n ef u s i o nw a sg e n e r a t e db yi n t r o d u -
cing a fragment coding for an a-helical spacer (tropo-
ninC, helix 5, see Figure 3B) between a 5’-luciferase
(deleted stop codon) and a 3’-eGFP (deleted start
codon) open reading frame (orf). The whole frame was
synthesized by overlapping PCR. Briefly, using pUHC-
131-1 [35] as template for luciferase and SK-eGFP as
template for the eGFP coding region, two PCR frag-
ments were synthesized that served as template for a
second PCR reaction delivering the final orf. The dele-
tion of the luciferase stop codon and the 5’-part of the
helical region was introduced into the 3’-oligo of lucifer-
ase while the 3’-part of the helical region and the dele-
tion of the eGFP start codon was contained within the
5’-oligo of eGFP (additional File 3). The dual reporter
gene has most useful properties as had been determined
in HtTA-1 cells: (i) luciferase combined half-life is
expanded to about 9 hours (~3 ×longer compared to
wildtype luciferase; [48]), and (ii) eGFP half life was
reduced to about 11 hours (~3 × shorter compared to
eGFP alone, [49]). The half-life of both reporter gene
activities was determined in HtTA-1 cells transduced by
ES.1-Ptet-T6. The enriched population was induced for
96 hours. Induction was stopped by addition of Dox to
the culture medium. Cells were taken directly from the
induced population and measured in FACS (mean
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activity determination. The lysates were stored at -20°C
for later analysis. The remaining cells were further culti-
vated in medium with Dox (off-state) and samples were
harvested as described above at 1, 2, 4, 8, 12, 24 and 48
hours. Linear regression analysis was employed to deter-
mine the time point within the linear range of decreas-
ing activity at which half of the activity was lost.
Unlike similar approaches to generate dual reporter
genes, using the renilla luciferase and aeqourea GFP (
[50]), no energy transfer is expected between the two
separated entities (emission luciferin 569 nm, excitation/
emission eGFP 488/509 nm, [51]). Thus, distinct mea-
surements of a highly sensitive luciferase activity and a
more dynamic eGFP are possible.
Plasmid constructs
The Ptet promoter units were constructed as exchangeable
modules in the pBluescript SKII+ plasmid backbone (Stra-
tagene). All cloning and modification steps were per-
formed according to established standard procedures [52]
or as recommended by the suppliers. Synthesis of the tet
operator heptamer was performed by subsequent anneal-
ing/ligation steps of pre-annealed ds-oligos, providing
individual overhangs and the spacers with random nucleo-
tide sequences between the operators. 5’ XhoI and 3’ Hind
III restriction sites were also included in the heptamer
design (additional File 1). A CMV-minimal promoter with
3’ SalI and NcoI restriction sites was introduced 3’ of the
heptamer. This synthetic fragment, termed TO7.3, was
cloned as XhoI/NcoI fragment into similar digested pBlue-
script SKII+ into which the orf of eGFP had already been
introduced (5’ EcoRI/NcoI and 3’ NotI), creating SK-
TO7.3g. EGFP was exchanged for lmg* (NcoI/NotI) lead-
ing to SK-TO7.3lmg* which served as basis for insertion
of all promoter variants of the Ptet-T series.
The promoter variants were either PCR amplified
using particular sense and antisense oligonucleotides or
generated as variants via site directed mutagenesis by
standard techniques, subcloned into pBluescript SKII+
and sequenced. The T1-T7 minimal promoters (addi-
tional file. 2) were introduced as HindIII/SalI fragments
into SK-TO7.3-lmg*, resulting in SK-Ptet-T1, -Ptet-T2,
-Ptet-T3, -Ptet-T4, -Ptet-T5, -Ptet-T6, and Ptet-T7.
Similar, the original Ptet-1 promoter [1], containing
the 42nt spaced tet operators and a CMV-minimal pro-
moter (-53/+75), was released as XhoI/NcoI from S2f-c
(LCMG) [17] and inserted into SK-TO7.3-lmg*, result-
ing in SK-Ptet-1.
The Ptet promoters were transferred as XhoI/NcoI
fragments into the pUHC-131 expression vector [35]
which contains the firefly luciferase reporter.
The retroviral SIN-vector “pES.1” used for the transfer
of the tet-response units had been described earlier
[46]. Individual inducible expression cassettes, consisting
of the tet operator heptamer, a minimal promoter, the
lmg* reporter gene were integrated as XhoI/NotI frag-
ments (released from respective SK-TO7."x"-lmg* plas-
mids) 5’ to the posttranscriptional regulatory element
(WPRE) of the woodchuck hepatitis virus [53]. Tran-
scription of the pES.1-Ptet-1 and pES.1-Ptet-T1 to Ptet-
T7 vectors is terminated at the polyadenylation signal of
the viral 3’-LTR.
Thus, irrespective of the plasmid or viral vector used
for transfer of the regulatory units, the surrounding
s e q u e n c e sw e r ek e p tc o n s t a n tt or u l eo u tt h ep o s s i b i -
lity of misleading results caused by unpredictable
effects of different spacing or altered sequence
elements.
Additional material
Additional file 1: Tet operator heptamer of the Ptet-T series of Ptet
promoters. The identical tet operator sequences are underlined, their
imperfect inverted repeats are shown in lower case. The center-to-center
distance between neighbouring operators is 36 nt, the respective centers
are capitalized and bold. Unique restriction sites used were 5’- XhoI and
3’- Hin dIII.
Additional file 2: Minimal promoters. Upstream (upper panel) and
downstream promoter sequences (lower panel) relative to the
transcription start site (+1) are aligned separately. 5’ (Hin dIII) and 3’ (Sal
I) restriction sites are shown in lower case, bold. The CMV-initiator (Inr) is
underlined. TATA-Box and TFIIB site are shaded in grey. The 5’-UTRs are
in lower case letters, for the TYMV 5’-UTR derived constructs also in
italics. Note that the Ptet-1 (not shown) and Ptet-T1 minimal promoter
sequences are identical, these two Ptet promoters differ only in their tet
operator array.
Additional file 3: Amino acid sequence of lmg* dual reporter. The
firefly luciferase orf is from aa 1-546 (upper case letters), the tropnonin C
spacer from aa 547-567 (underlined), and the eGFP-orf from aa 568-807
(lower case letters). The last amino acid of the original luciferase orf (a
leucine) together with the stop codon has been removed, as well as the
original start codon of the eGFP-orf.
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